Drug Discovery

#Biopharmaceutical #Drug development #Drug discovery #mRNA

Evotec and Takeda enter RNA targeting drug discovery alliance

Evotec has entered into a multi-RNA target alliance with Takeda Pharmaceutical with the goal to discover and develop RNA targeting small molecule therapeutics for highly attractive targets that are difficult to address via more conventional approaches. Evotec and Takeda will jointly identify and develop small molecules targeting a range of… Read More

#News

#Covid-19 #Drug development #Drug discovery #Immunology / Virology & Vaccines #Podcast #Sartorius

Advances in cell and protein analysis for virology research

This free to listen podcast and DDW exclusive, features Dr Hongshan Li, Applications Manager, Sartorius, discussing advances in cell and protein analysis for virology research. This episode only available to download here, examines virology research – what’s currently happening in the sector and how new advances in technology are helping push forward… Read More

#Podcasts

#Cancer research #Drug development #Institute of Cancer Research #Oncology #Therapeutics

Resistance-busting ICR drug enters clinical trial

The Institute of Cancer Research (ICR), London, has discovered a drug that could counteract drug resistance in patients with cancers including acute myeloid leukaemia. It has entered a Phase I clinical trial at The Royal Marsden NHS Foundation Trust. The drug, now called EP0042, is a dual inhibitor of cancer-driving… Read More

#Cancer Research #Editor's Choice #News

#Biotechnology #Drug delivery #Drug development #Events

Join NanoTemper Technologies’ Prometheus Panta tour

NanoTemper Technologies will be running a case study and walk through of Prometheus Panta. Join the company on 30 March to learn how to make formulation workflow more efficient with multi-parameter stability characterisation. This event will provide new perspectives on data and will look at how running thermal unfolding, particle… Read More

#News

#Biologics / Biotechnology #Drug development #Events #Exhibition

SLAS Europe 2021 registration now open

Registration is now open for the SLAS Europe 2021 Hybrid Conference and Exhibition, which aims to connect people and advance science. There are flexible rates and registration options for both the in-person events in Vienna and Austria, and online, from June 22-25, 2021. SLAS Europe 2021 Hybrid offers a programme… Read More

#News

#Antibodies #Drug development #Drug discovery #Huntington's disease

Collaboration to develop landmark novel antibody therapy for Huntington’s

Alchemab, a biotech company harnessing the power of naturally protective antibodies, has been awarded a UK Biomedical Catalyst early award grant from Innovate UK to support its collaboration with Medicines Discovery Catapult and the development of a novel disease-modifying antibody therapy for Huntington’s disease. Using its novel approach, Alchemab has… Read More

#News

#Biologics / Biotechnology #Biotherapeutics #Cancer immunotherapy #Drug discovery

Bicara Therapeutics launches biologics for cancer immunotherapy

Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics designed to spur a potent and durable immune response in the tumour microenvironment, launched with a US$40 million investment from Biocon. The financing will be used to advance a pipeline of first-in-class bifunctional antibodies developed by a global team, including a… Read More

#Cancer Research #News

#Drug delivery #Drug development #Drug discovery

Horizon Therapeutics acquires Viela Bio

Discovery, development and commercialisation company Horizon Therapeutics has announced the completion of the acquisition of drug developer, Viela Bio. Tim Walbert, chairman, president and chief executive officer, Horizon, said: “With its deep, mid-stage biologics pipeline, strong R&D team and on-market medicine UPLIZNA, Viela is a strong complementary strategic fit with… Read More

#News

#Alzheimer's #Dementia #Drug development #Drug discovery

Researchers discover critical step in formation of fatal brain diseases

A research team from Imperial College London and the University of Zurich have identified what causes normal proteins to convert to diseased form, causing conditions like Creutzfeldt-Jakob disease (CJD) and Kuru. The researchers also tested a way to block the process, which could lead to new drugs for combatting such… Read More

#News

#Drug delivery #Drug development #Drug discovery #Parkinson's

Researchers collaborate to design treatment for Parkinson’s disease

‍IRICoR, a pan-Canadian drug discovery and research commercialisation centre, Université de Montréal (UdeM), the Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal, and Valence Discovery, AI-enabled drug designer, have announced a collaboration focussing on the discovery of novel drug candidates for the treatment of levodopa-induced dyskinesia… Read More

#Editor's Choice #News #Trending News

#AI #Antibody #Drug discovery

Antiverse raises funds to advance its AI antibody drug discovery platform

Antiverse, a biotechnology company developing a computational antibody drug discovery platform, has raised seed funding totalling £1.4 million ($2 million USD), comprising new investment and match funding from the UKI2S Innovate Accelerator. The funding will be used to further develop Antiverse’s AI antibody drug discovery platform, which rapidly and accurately… Read More

#News

#Diabetes #Drug development #Drug discovery #Research study #Type 2 diabetes

Two new diabetes drugs may work better for Asian people

According to new research, two new but commonly-used diabetes drugs, one of which is also now approved for use in heart failure in people with or without diabetes, might be more effective in people with an Asian background than in people with a White… Read More

#News

#Assay #Assay development optimisation & technology #Drug discovery #Research

BellBrook Labs given NIH funding for work on antitumour immunity 

Drug discovery company BellBrook Labs has been awarded a $300,000 Phase I Small Business Innovative Research grant to develop and validate HTS assays for the discovery of small-molecule antagonists of TREX1. Immunotherapy approaches such as immune checkpoint blockade are said to be transforming oncology. However, many patients do not respond to… Read More

#News

#Covid-19 #Drug development #Drug discovery #Research study #Study

UK researchers identify inflammatory protein linked to severe COVID-19

Patients with severe COVID-19 show increased levels of a key protein in their blood, which researchers believe may help identify those most at risk. In an analysis of more than 500 COVID-19 patients across the UK, researchers identified several inflammatory markers in blood which increased within the early stages of… Read More

#Covid-19 #News

#Biopharmaceuticals #Biotechnology #Drug discovery #Market reporting #Pharmatech

Pharma report predicts growth of contract services by 2025

A post-pandemic pharma report from CPhI predicts the next few years will deliver strong growth in pharma innovation, with oncology and rare diseases potentially the biggest beneficiaries of positive Covid-19 legacies – including accelerated development timelines, remote trials and new technologies in genetic and target screening. The report anticipates breakthroughs in… Read More

#Market Reports #News

#Biotechnology #Drug development #Molecular research

AMRI scoops Forbes’ best employer accolade

Albany Molecular Research (AMRI), provider of advanced contract research, development and manufacturing solutions, has been included in America’s Best Employers 2021 list, published by Forbes. AMRI was included in the Drugs and Biotechnology industry category of the ranking. Its 3,100 employees provide scientific solutions across the R&D and manufacturing continuum… Read More

#News